Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Egypt | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Egypt

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About 
      • Novartis in Egypt 
      • Strategy 
      • Diversity and Inclusion 
      • People and Culture 
      • Innovative Medicines 
      • Products 
      • Country Leadership Team 
        • Sherif Amin 
      A girl with a flower About
    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Products 
      • Adverse Event Reporting 
      • Patient Partner Panel 
      A couple holding hands Patients and Caregivers
    • Healthcare Professionals 
      • Products 
      • Novartis Pipeline 
      • Adverse Event Reporting 
      • Novartis Clinical Trials 
      • Information for Physicians 
      Healthcare Professional Healthcare Professionals
    • ESG 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
      • Ethics, Risk and Compliance 
      • Access 
      • Environmental Sustainability 
      • Global Health 
      ESG ESG
    • News 
      • News Archive 
      • Media Releases 
      • Featured News 
      News News
    • Careers 
      • Career Search 
      • Meet the teams 
      • Personal Growth 
      • Early Talent 
      • How We Work 
      • Well-being 
      • Diversity and Inclusion 
      • Awards and Recognition 
      Careers Careers
    • Coronavirus 
      covid 10 grey image_0 COVID-19 Information Center
    • Contacts 
    Homepage Novartis in Egypt Home
  1. Home
  2. News
  3. News Archive
News Archive Navigation
  • All
  • Media Release
  • Featured News
icon
News Archive Navigation Language
  • English
  • French
  • German

March 2020

  • covid 10 grey image_0
    Featured NewsMar 21, 2020
    COVID-19 Information Center

To report an adverse event or any drug related issues concerning Novartis medicinal products; please contact Novartis Patient Safety: Tel: +202 22861000 - Press 3 for reporting an adverse event. Fax: 002 02 26031702. E-mail: [email protected]

للإبلاغ عن أثر جانبى أو أي مشكلة دوائية متعلقة بمنتجات نوفارتس الطبية او الاجهزة ؛ يرجى الاتصال بقسم اليقظة الدوائية في شركة نوفارتس
[email protected] البريد الإلكترونى
 +202 22861000 : الهاتف
ثم اضغط 3 للإبلاغ عن أثر جانبي او الخط الأرضى 20224524036+

 +2 02 26031702 : الفاكس

Novartis Egypt

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • News
  • Careers
Media Center
  • News Archive
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Other Novartis websites
  • Global site
Footer Bottom
© 2023 Novartis AG
  • Privacy Policy
  • Terms of Use
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for an audience in Egypt.